April. 29-May, 2, 2022 | Philadelphia
Abstract Submission Deadline
Tuesday, Nov. 2, 2021, at 5 pm CST
Visit abstractscorecard.com and log in using your MyAANS username and password to submit an abstract.
Abstract Title — Titles should read as you want it to appear in meeting publications. Use title case capitalization, do not use all CAPITAL LETTERS and do not put a period at the end of the title. Example: This is a Properly Formatted Abstract Title
Presentation Preference — Please note whether the preferred format is an oral presentation, poster or both. Note: Selecting “Oral Only” is indicating your preferred choice and is not a guarantee.
Presenting Author (First Author) — The presenting author is the individual who is submitting the abstract and is required to register and attend the meeting.
Co-authors — List full names with credentials and email addresses.
Primary and Secondary Subject Categories
Abstract Body — Include introduction, methods, results and conclusion sections. Text is limited to 300 words.
Additional Information — This includes elements such as previous presentation of abstract, FDA approval, industry employment status, medical student/resident designation, senior author information, funding/database questions and award consideration. Note: Check the appropriate box(es) to be considered for awards.
Disclosure — Disclosure is required for each presenting author, as well as agreement with Terms and Conditions.
Review Work — There is a “Preview Abstract” option to review your abstract.
Please proofread — before submission to avoid errors. The AANS will not make any edits.
Submit — All tasks must be completed and the abstract status must read “COMPLETE” on the submission site home screen for the abstract to be included in grading. A confirmation email will be sent.
Note — Abstracts cannot contain advertising, trade names or a product-group messaging. Include generic names or terms in your abstract content. If the abstract includes trade names, names from several companies should be used — not just trade names from a single company — to present all available treatment options. If trade names or company names are included in your abstract, the AANS reserves the right to remove them to ensure all scientific content is free from commercial bias.
Yes, you can make edits until the submission deadline.
Once the review process begins, no changes to the submitted abstracts are allowed — no exceptions. Any typographical or spelling errors, improperly formatted titles, missing co-authors, etc., will not be edited by anyone at the AANS.
It is the responsibility of the submitter to review and verify all work submitted. Please remember, after making any changes to your abstract, you must save and resubmit the abstract, even if it was previously submitted. The abstract status must read “COMPLETE” on the submission site home screen for the abstract to be included in grading. A confirmation email will be sent for every resubmission.
Oral Presentations The highest-ranked abstracts are selected for presentation in one of the plenary, scientific or section sessions. These sessions take place Saturday and Sunday of the meeting. When uploading slide presentations, the aspect ratio should be 16:9.
The oral presentation upload site opens Monday, March 28, 2022.
E-posters E-posters are a digital presentation of an abstract and can be viewed through the entirety of the AANS Annual Scientific Meeting on the meeting app, at app kiosks in the designated e-poster area at the convention center and on the virtual platform. Presenting authors have the opportunity to upload a supplemental PDF poster or a prerecorded video slide presentation to accompany their original abstract submission.
The e-poster upload site opens Monday, March 7 and closes Monday, March 21, 2022. Late uploads are not accepted – no exceptions.
All abstract submitters will be notified by email in mid-January 2022 regarding their abstract status.
No, the AANS does not allow for any charts, graphs or images in the abstract submission process.
Each submission is blindly reviewed by neurosurgeons whose specialty is within the category of submission. Last year, the committee of reviewers had more than 125 neurosurgeons participate in the review process.